Reshape Lifesciences (RSLS) ์ฃผ์
์์ฅ ๊ธฐ์ . 10์ 2026 ๊ธฐ์ค Reshape Lifesciences์ ์ฃผ๊ฐ, ์ฌ์ ๊ฐ์, ์์๋์ด์ผ ํ ํต์ฌ ์ ๋ณด๋ฅผ ์ ๋ฆฌํ์ต๋๋ค.
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The Diabetes Bloc-Stim Neuromodulation system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0 FLEX, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
์ข ๋ชฉ ์๊ฐ
ReShape Lifesciences Inc
RSLS
ํ์ฌ๊ฐ
$4.77
12๊ฐ์ ์์ ์์ต
1,115.93%
์นํฐ
N/A
์ฐ์
N/A
ํฐ์ปค
RSLS
์๊ฐ์ด์ก
$7.64M
12๊ฐ์ ์์ ์์ต
1,115.93%
์นํฐ
N/A
์ฐ์
N/A
6๊ฐ์ ์ฑ์ฅ ์ฑ๊ณผ
์ฃผ๊ฐ ์ฑ๊ณผ ์์ฝ
์ ๋๋ฆฌ์คํธ ํ๊ฐ
Analysts strongly recommend buying ReShape Lifesciences' stock, with a significant target price of $58.
์ฌ๋ฌด ๊ฑด์ ์ฑ
ReShape Lifesciences is performing well with strong revenue and cash flow, indicating solid financial health.
์ฑ์ ๋ฌด๋ฃ๋ก ๋ค์ด๋ก๋ํ๊ณ ๋ ๋ง์ ์ข ๋ชฉ ๋ณด๊ธฐ
60์ด๋ฉด ์ถฉ๋ถํฉ๋๋ค.
์ Nemo์ ํจ๊ป ํฌ์ํด์ผ ํ ๊น์?
์์๋ฃ ๋ฌด๋ฃ
์ฃผ์, ETF ๋ฑ์ ์์๋ฃ ์์ด ๊ฑฐ๋ํ์ธ์. ์์ต์ ๋ ๋ง์ด ์งํค์ธ์.
์ ๋ขฐํ ์ ์๋ ๊ท์ ๊ธฐ๊ด ์ธ๊ฐ
2015๋ ๋ถํฐ Exinity Group์ ์ผ์์ผ๋ก, ์ ์ธ๊ณ 100๋ง ๋ช ์ด์์ ๊ณ ๊ฐ์๊ฒ ์๋น์ค๋ฅผ ์ ๊ณตํฉ๋๋ค.